To the best of our knowledge this is the first study looking at the effects of PI3K pathway activation through a combination of PIK3CA gene mutations, ERBB family gene mutations and low PTEN expression on pCR in the neoadjuvant treatment of HER2-positive breast cancer. This evidence concerns the gene EGFR and breast carcinoma.